Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
REPL
Strong SellHot AirReplimune Group, Inc. · Healthcare · United States · $1.5B · Avg Vol: $73M/d
COMPANY DESCRIPTION
Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer. Its lead product candidates are designed to selectively replicate in cancer cells and express immune-stimulating proteins, enhancing the body's anti-tumor response. The company's innovative oncolytic virus platform holds potential to address a broad range of solid tumors, positioning it in a highly specialized and rapidly evolving segment of the oncology market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | 42.8M | 193.2M | — |
| EPS | -2.26 | -2.99 | -3.24 | -3.07 | -3.38 | — | -3.15 | -2.98 | -2.04 | — |
| Shares | 47.3M | 56.7M | 61.4M | 77.1M | 82.7M | +74.7% | 94.2M | — | — | — |
| Debt | 32.8M | 60.8M | 75.9M | 76.2M | 111.6M | 35.8% | 112.0M | — | — | — |
| Equity | 411.2M | 555.3M | 374.5M | 415.8M | 166.2M | -20.3% | — | — | — | — |
| Op CF | -82.2M | -128.1M | -185.5M | -192.3M | -280.3M | — | -279.1M | — | — | — |
| Inv CF | -1.8M | -142.5M | 97.2M | -23.8M | 310.8M | — | — | — | — | — |
| Fin CF | 6.6M | 311.3M | 16.3M | 252.4M | 66.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of REPL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| REPL | Replimune Group, Inc.(you) | $1.5B | 19 | Strong Sell |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | 22 | Sell |
| VOR | Vor Biopharma Inc. | $1.3B | 20 | Sell |
| ABSI | Absci Corporation | $1.5B | 17 | Strong Sell |
| NVAX | Novavax, Inc. | $1.5B | 16 | Strong Sell |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.4B | 22 | Sell |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 20 | Sell |
| JBIO | Jade Biosciences, Inc. | $1.3B | 24 | Sell |
| CGEM | Cullinan Therapeutics, Inc. | $1.3B | 26 | Sell |
| MNKD | MannKind Corporation | $1.3B | 25 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%